to-BBB and Lundbeck to join forces on brain delivery of antibodies for CNS diseases
to-BBB and H. Lundbeck A/S are entering into a research collaboration to evaluate delivery of antibodies to the brain for central nervous system (CNS) diseases. This research could provide the backbone of new emerging therapies for unserved brain diseases.
“We are very pleased to collaborate with Lundbeck,” says Pieter Gaillard, CSO of to-BBB. “to-BBB’s brain delivery technology combined with Lundbeck’s strong knowledge in the area of CNS disorders, should result in further progress to improve the lives of patients with devastating brain diseases.”
Lundbeck is an international pharmaceutical company engaged in research to find new drugs for treatment of CNS disorders, including depression, schizophrenia, Alzheimer’s disease and Parkinson’s disease. The collaboration with to-BBB could provide Lundbeck with an opportunity to improve the brain delivery of therapeutic antibodies addressing CNS diseases.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous